tetano
Editor, Senior Moderator
PLoS One
. 2021 Nov 17;16(11):e0259902.
doi: 10.1371/journal.pone.0259902. eCollection 2021.
Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection
Yonghou Jiang[SUP] 1 [/SUP], Fergal Duffy[SUP] 1 [/SUP], Jennifer Hadlock[SUP] 2 3 [/SUP], Andrew Raappana[SUP] 1 [/SUP], Sheila Styrchak[SUP] 1 [/SUP], Ingrid Beck[SUP] 1 [/SUP], Fred D Mast[SUP] 1 [/SUP], Leslie R Miller[SUP] 1 [/SUP], William Chour[SUP] 2 4 5 [/SUP], John Houck[SUP] 1 [/SUP], Blair Armistead[SUP] 1 [/SUP], Venkata R Duvvuri[SUP] 2 [/SUP], Winnie Yeung[SUP] 1 [/SUP], Micaela Haglund[SUP] 1 [/SUP], Jackson Wallner[SUP] 1 [/SUP], Julie A Wallick[SUP] 3 6 [/SUP], Samantha Hardy[SUP] 1 [/SUP], Alyssa Oldroyd[SUP] 1 [/SUP], Daisy Ko[SUP] 1 [/SUP], Ana Gervassi[SUP] 1 [/SUP], Kim M Murray[SUP] 2 [/SUP], Henry Kaplan[SUP] 7 [/SUP], John D Aitchison[SUP] 1 8 [/SUP], James R Heath[SUP] 2 [/SUP], D Noah Sather[SUP] 1 8 [/SUP], Jason D Goldman[SUP] 3 6 9 [/SUP], Lisa Frenkel[SUP] 1 8 [/SUP], Whitney E Harrington[SUP] 1 8 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (AT1R-Ab).
Methods: We compared prevalence and levels of AT1R-Ab in COVID-19 cases with mild or severe disease to age and sex matched negative controls utilizing multivariate logistic and quantile regression adjusted for comorbidities including hypertension, diabetes, and heart disease.
Results: There were trends toward increased prevalence (50% vs. 33%, p = 0.1) and level of AT1R-Ab (median 9.8 vs. 6.1 U/mL, p = 0.06) in all cases versus controls. When considered by COVID-19 disease severity, there was a trend toward increased prevalence of AT1R-Ab (55% vs. 31%, p = 0.07), as well as significantly higher AT1R-Ab levels (median 10.7 vs. 5.9 U/mL, p = 0.03) amongst individuals with mild COVID-19 versus matched controls. In contrast, the prevalence (42% vs. 37%, p = 0.9) and level (both medians 6.7 U/mL, p = 0.9) of AT1R-Ab amongst those with severe COVID-19 did not differ from matched controls.
Conclusions: These findings support an association between COVID-19 and AT1R-Ab, emphasizing that vascular pathology may be present in individuals with mild COVID-19 as well as those with severe disease.
. 2021 Nov 17;16(11):e0259902.
doi: 10.1371/journal.pone.0259902. eCollection 2021.
Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection
Yonghou Jiang[SUP] 1 [/SUP], Fergal Duffy[SUP] 1 [/SUP], Jennifer Hadlock[SUP] 2 3 [/SUP], Andrew Raappana[SUP] 1 [/SUP], Sheila Styrchak[SUP] 1 [/SUP], Ingrid Beck[SUP] 1 [/SUP], Fred D Mast[SUP] 1 [/SUP], Leslie R Miller[SUP] 1 [/SUP], William Chour[SUP] 2 4 5 [/SUP], John Houck[SUP] 1 [/SUP], Blair Armistead[SUP] 1 [/SUP], Venkata R Duvvuri[SUP] 2 [/SUP], Winnie Yeung[SUP] 1 [/SUP], Micaela Haglund[SUP] 1 [/SUP], Jackson Wallner[SUP] 1 [/SUP], Julie A Wallick[SUP] 3 6 [/SUP], Samantha Hardy[SUP] 1 [/SUP], Alyssa Oldroyd[SUP] 1 [/SUP], Daisy Ko[SUP] 1 [/SUP], Ana Gervassi[SUP] 1 [/SUP], Kim M Murray[SUP] 2 [/SUP], Henry Kaplan[SUP] 7 [/SUP], John D Aitchison[SUP] 1 8 [/SUP], James R Heath[SUP] 2 [/SUP], D Noah Sather[SUP] 1 8 [/SUP], Jason D Goldman[SUP] 3 6 9 [/SUP], Lisa Frenkel[SUP] 1 8 [/SUP], Whitney E Harrington[SUP] 1 8 [/SUP]
Affiliations
- PMID: 34788328
- DOI: 10.1371/journal.pone.0259902
Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (AT1R-Ab).
Methods: We compared prevalence and levels of AT1R-Ab in COVID-19 cases with mild or severe disease to age and sex matched negative controls utilizing multivariate logistic and quantile regression adjusted for comorbidities including hypertension, diabetes, and heart disease.
Results: There were trends toward increased prevalence (50% vs. 33%, p = 0.1) and level of AT1R-Ab (median 9.8 vs. 6.1 U/mL, p = 0.06) in all cases versus controls. When considered by COVID-19 disease severity, there was a trend toward increased prevalence of AT1R-Ab (55% vs. 31%, p = 0.07), as well as significantly higher AT1R-Ab levels (median 10.7 vs. 5.9 U/mL, p = 0.03) amongst individuals with mild COVID-19 versus matched controls. In contrast, the prevalence (42% vs. 37%, p = 0.9) and level (both medians 6.7 U/mL, p = 0.9) of AT1R-Ab amongst those with severe COVID-19 did not differ from matched controls.
Conclusions: These findings support an association between COVID-19 and AT1R-Ab, emphasizing that vascular pathology may be present in individuals with mild COVID-19 as well as those with severe disease.